FGFR2 and non-small cell lung carcinoma: Additional studies will be required to determine the impact of these kinase domain mutations on FGFR2 fusion protein as well as it will be important to establish the extent to which preexisting FGFR2 mutations affect the time to treatment failure, as observed in non-small cell lung cancer carrying EGFR-mutation.